Literature DB >> 34008137

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals.

Tushar Srivastava1, Nicholas R Latimer2, Paul Tappenden2.   

Abstract

State transition models are used to inform health technology reimbursement decisions. Within state transition models, the movement of patients between the model health states over discrete time intervals is determined by transition probabilities (TPs). Estimating TPs presents numerous issues, including missing data for specific transitions, data incongruence and uncertainty around extrapolation. Inappropriately estimated TPs could result in biased models. There is limited guidance on how to address common issues associated with TP estimation. To assess current methods for estimating TPs and to identify issues that may introduce bias, we reviewed National Institute for Health and Care Excellence Technology Appraisals published from 1 January, 2019 to 27 May, 2020. Twenty-eight models (from 26 Technology Appraisals) were included in the review. Several methods for estimating TPs were identified: survival analysis (n = 11); count method (n = 9); multi-state modelling (n = 7); logistic regression (n = 2); negative binomial regression (n = 2); Poisson regression (n = 1); and calibration (n = 1). Evidence Review Groups identified several issues relating to TP estimation within these models, including important transitions being excluded (n = 5); potential selection bias when estimating TPs for post-randomisation health states (n = 2); issues concerning the use of multiple data sources (n = 4); potential biases resulting from the use of data from different populations (n = 2), and inappropriate assumptions around extrapolation (n = 3). These issues remained unresolved in almost every instance. Failing to address these issues may bias model results and lead to sub-optimal decision making. Further research is recommended to address these methodological problems.

Entities:  

Year:  2021        PMID: 34008137     DOI: 10.1007/s40273-021-01034-5

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

Review 1.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

2.  Tutorial in biostatistics: competing risks and multi-state models.

Authors:  H Putter; M Fiocco; R B Geskus
Journal:  Stat Med       Date:  2007-05-20       Impact factor: 2.373

Review 3.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.

Authors:  Dean Fergusson; Shawn D Aaron; Gordon Guyatt; Paul Hébert
Journal:  BMJ       Date:  2002-09-21

4.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

5.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.

Authors:  Uwe Siebert; Oguzhan Alagoz; Ahmed M Bayoumi; Beate Jahn; Douglas K Owens; David J Cohen; Karen M Kuntz
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

6.  Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.

Authors:  Xabier García-Albéniz; Joan Maurel; Miguel A Hernán
Journal:  Int J Cancer       Date:  2014-11-03       Impact factor: 7.396

Review 7.  Current recommendations on the estimation of transition probabilities in Markov cohort models for use in health care decision-making: a targeted literature review.

Authors:  Elena Olariu; Kevin K Cadwell; Elizabeth Hancock; David Trueman; Helene Chevrou-Severac
Journal:  Clinicoecon Outcomes Res       Date:  2017-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.